In addition to prostate biopsies, there are another 4.2 million biopsies performed in the United States and 18 million worldwide that could potentially be diagnosed with the 3DBiopsy system. These include organs in which precisely identifying cancer location is critical to treatment, such as the liver, kidney, and thyroid. Breast cancer is another ideal application, as it can have a similar quality-of-life impact on a woman as prostate cancer has on a man. 3DBiopsy plans to develop additional technology to expand its first prostate biopsy platform to address these other clinical opportunities.
*Investigational device. Not available for sale in the United States.
Brad J. Buscher
Chairman of the Board
Nelson N. Stone, MD
President, Chief Executive Officer and Founder
James R. Rosa
Vice President, Regulatory and Quality Assurance
Todd J. Anderson
Chief Financial Officer
E. David Crawford, MD
Chief Medical Advisor and Founder